Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus platinum-based chemotherapy followed by niraparib maintenance in platinum-sensitive recurrent ovarian, tubal, or peritoneal cancer
2018-000366-11Phase 3Recruiting
- Sponsor
- Grupo Español de Investigación en Cáncer de Ovario
- Start
- Aug 2018
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of atezolizumab, niraparib and carboplatin in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Grupo Español de Investigación en Cáncer de Ovario. Primary endpoint: Progression-free survival. Started Aug 2018; status: recruiting.
02
Drugs
atezolizumabniraparibcarboplatin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2018-000366-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000366-11.